The Global Leukodystrophy Initiative is thrilled to announce a new federally-funded research program known as the Global Leukodystrophy Initiative Clinical Trials Network (GLIA-CTN).
The GLIA-CTN is a consortium of scientists, industry stakeholders, and patient advocacy leaders working together to promote advances in the diagnosis and treatment of leukodystrophies. Specifically, it seeks to create a robust research infrastructure that will allow for collection and analysis of longitudinal natural history data, development of novel clinical outcome assessments, and identification of surrogate biomarkers – ultimately paving the way for transformative therapeutic trials across the leukodystrophies.
In parallel to these approaches, the GLIA-CTN will work closely with a diverse group of stakeholders to promote disease awareness and education, advocate for the adoption of universal newborn screening and early diagnostic programs, and establish clinical guidelines to support the short- and long-term care of individuals living with leukodystrophies.
Please click here to learn more about the NIH Rare Disease Clinical Research Network (RDCRN) and its participation research consortia.